Susan Greenfield, Founder and CEO of Neuro-Bio Ltd, shared her insights on the challenges of developing Alzheimer’s disease treatments, and the fundamental flaw with approaches to date on the “European Biopharmaceutical Review”.

To read the full article, click the following: Neuro-Bio. This article is taken from European Biopharmaceutical Review July 2022, pages 40-42. © Samedan Ltd